Effects of Combined Non-invasive Brain Stimulation (NIBS) Technique on Motor Recovery in Subacute Stroke Patients as Explained by Mitochondrial Mechanism

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211207001

Enrollment

Registered

2021-12-07

Start date

2016-11-09

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subacute stroke ischemic stroke hemorrhagic stroke subacute stroke ischemic stroke hemorrhagic stroke

Interventions

Low-frequency rTMS of 1 Hz, 90% RMT for 20 minutes and applied the figure-of-eight coil tangentially to the scalp. After that, they were stimulated with the cathodal tDCS of 2 mA for 20 minutes while

Experimental Device,Sham Comparator Other

low-frequency rTMS with cathodal tDCS,sham low-frequency rTMS &amp

cathodal tDCS

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Thai nationality (2) age 20-80 years old (3) diagnosed with ischemic or hemorrhagic stroke within 6 months (4) following at least 2-step verbal command (5) sitting for at least 2 hours per day (6) having a Brunnstrom stage in any arm, hand or leg equal or more than stage 3

Exclusion criteria

Exclusion criteria: (1) recurrent stroke (2) other brain pathologies such as brain tumor, traumatic brain injury (3) unstable medical conditions (4) neurostimulator implantation (5) pacemaker implantation (6) metallic components in skull or ear (7) seizure (8) using addictive substance (9) pregnancy (10) previously treated by rTMS or tDCS

Design outcomes

Primary

Measure	Time frame
Fugl-Meyer Assessment baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline Fugl-Meyer Assessment Scale	—

Secondary

Measure	Time frame
Medical Research Council for muscle power baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline Medical Research Council Scale,Brunnstrom Stage of arm, hand and leg baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline Brunnstrom stage,Motor Activity Log-14 baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline This test assessed the use of weak arm and hand for the 14 activities in daily life.,10-meter walk test baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline This test was used to evaluate in the patients with the fastest pace of 10 meters by recording time only 6 meters in the middle part,Montreal Cognitive Assessment pre-stimulation (baseline), the 3rd and 5th weeks after pre-stimulation Cognitive Function Assessment,Mini-Mental State Examination pre-stimulation (baseline), the 3rd and 5th weeks after pre-stimulation Cognitive Function Assessment,cellular oxidative stress levels the 3rd and 5th weeks from baseline Dichlorohydro-Fluorescein Diacetate dye intensity,mitochondrial oxidative stress levels the 3rd and 5th weeks from baseline The fluorescent intensity of MitoSOX,Plasma oxidative stress the 3rd and 5th weeks from baseline Plasma 8-isoprostane levels ,Plasma oxidative inflammation the 3rd and 5th weeks from baseline Plasma tumor necrosis factor alpha	—

Measure

Time frame

Medical Research Council for muscle power baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline Medical Research Council Scale,Brunnstrom Stage of arm, hand and leg baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline Brunnstrom stage,Motor Activity Log-14 baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline This test assessed the use of weak arm and hand for the 14 activities in daily life.,10-meter walk test baseline (one week prior to intervention), immediately after intervention at the 1st, 2nd, 3rd weeks and the 4th, 5th, 9th weeks after the baseline This test was used to evaluate in the patients with the fastest pace of 10 meters by recording time only 6 meters in the middle part,Montreal Cognitive Assessment pre-stimulation (baseline), the 3rd and 5th weeks after pre-stimulation Cognitive Function Assessment,Mini-Mental State Examination pre-stimulation (baseline), the 3rd and 5th weeks after pre-stimulation Cognitive Function Assessment,cellular oxidative stress levels the 3rd and 5th weeks from baseline Dichlorohydro-Fluorescein Diacetate dye intensity,mitochondrial oxidative stress levels the 3rd and 5th weeks from baseline The fluorescent intensity of MitoSOX,Plasma oxidative stress the 3rd and 5th weeks from baseline Plasma 8-isoprostane levels ,Plasma oxidative inflammation the 3rd and 5th weeks from baseline Plasma tumor necrosis factor alpha

—

Countries

Thailand

Contacts

Public ContactPakorn Wivatvongvana

Chiang Mai University

pwivatvo@gmail.com053936322

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026